CAMKIIγ is a targetable driver of multiple myeloma through CaMKIIγ/ Stat3 axis

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Aberrant Calcium/calmodulin-dependent protein kinase II gamma (CaMKIIγ) activation is implicated in leukemia and T-cell lymphoma.
• The role of CaMKIIγ in multiple myeloma (MM) pathogenesis and therapeutic potential remains largely unexplored.

Purpose of the Study:

• To investigate the role of CaMKIIγ in the development and progression of multiple myeloma (MM).
• To evaluate CaMKIIγ as a potential therapeutic target for MM treatment.

Main Methods:

• Analysis of CaMKIIγ expression in human MM samples.
• In vitro studies involving ectopic expression and knockdown of CaMKIIγ in MM cell lines.
• In vivo studies to assess the effect of CaMKIIγ on MM progression.
• Examination of downstream signaling pathways, including ERK and STAT3.

Main Results:

• CaMKIIγ was aberrantly activated in human MM, with expression levels correlating positively with disease progression and poor prognosis.
• Ectopic CaMKIIγ expression enhanced MM cell growth, colony formation, and cell cycle progression while inhibiting apoptosis.
• CaMKIIγ knockdown suppressed MM cell growth both in vitro and in vivo.
• CaMKIIγ overexpression upregulated phosphorylated ERK (p-ERK) and phosphorylated STAT3 (p-Stat3) levels, while suppression of CaMKIIγ had opposite effects.

Conclusions:

• CaMKIIγ is frequently dysregulated in multiple myeloma (MM) and critically supports MM cell growth via the STAT3 signaling pathway.
• CaMKIIγ represents a promising therapeutic target for MM.
• Small-molecule berbamine analogues show potential for pharmacological intervention against CaMKIIγ in MM.